Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 1/20 | 0.62 |
| ▸ | FCER2 | P06734 | 5/20 | 0.59 |
| ▸ | MMP9 | P14780 | 4/20 | 0.53 |
| ▸ | MMP8 | P22894 | 2/20 | 0.53 |
| ▸ | MC5R | P33032 | 2/20 | 0.53 |
| ▸ | MC1R | Q01726 | 2/20 | 0.53 |
| ▸ | MME | P08473 | 2/20 | 0.51 |
| ▸ | ACE | P12821 | 2/20 | 0.51 |
| ▸ | CPA1 | P15085 | 2/20 | 0.51 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.51 |
| ▸ | ACACB | O00763 | 1/20 | 0.51 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.50 |
| ▸ | HTR2B | P41595 | 1/20 | 0.50 |
| ▸ | IDE | P14735 | 3/20 | 0.49 |
| ▸ | MMP3 | P08254 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL607214 | 0.87 | MME (0.65) | TACR1MMP9MMP8MMEACE | |
| SCHEMBL8712438 | 0.87 | MME (0.65) | TACR1MMP9MMP8MMEACE | |
| SCHEMBL607215 | 0.87 | MME (0.65) | TACR1MMP9MMP8MMEACE | |
| SCHEMBL29386502 | 0.87 | MME (0.65) | TACR1MMP9MMP8MMEACE | |
| SCHEMBL30995920 | 0.86 | FCER2 (0.63) | TACR1FCER2MMP9MMP8MC5R | |
| SCHEMBL22788735 | 0.86 | TACR1 (0.62) | TACR1FCER2MMP9MMP8MME | |
| SCHEMBL16348725 | 0.85 | FCER2 (0.55) | TACR1FCER2MMP9MMP8MC5R | |
| SCHEMBL31618325 | 0.85 | FCER2 (0.55) | TACR1FCER2MMP9MMP8MC5R | |
| SCHEMBL8712763 | 0.84 | TACR1 (0.72) | TACR1MMP9MMP8MMEACE | |
| SCHEMBL6664566 | 0.84 | TACR1 (0.72) | TACR1MMP9MMP8MMEACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3357513-B1 | PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | KANGPU BIOPHARMACEUTICALS LTD (CN) | 2023-10-25 | — | — | EP | disclosed |
| EP-3527210-B1 | COMBINED COMPOSITION COMPRISING A BENZOHETEROCYCLIC COMPOUND AND AN ANDROGEN RECEPTOR PATHWAY MODULATOR AND USES THEREOF | KANGPU BIOPHARMACEUTICALS LTD (CN) | 2021-06-09 | — | — | EP | disclosed |
| EP-3357513-A1 | PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | Kangpu Biopharmaceuticals, Ltd. (CN) | 2018-08-08 | — | — | EP | disclosed |
| US-20050058725-A1 | Combination therapy including a matrix metalloproteinase inhibitor and an antineoplastic agent | MCKEARN JOHN P (US) | 2005-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050058725-A1 | Combination therapy including a matrix metalloproteinase inhibitor and an antineoplastic agent | MMP3, MMP10, MMP25 | TACR1 3104/4885FCER2 3499/4885MMP9 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.